Scioderm Inc.
Treating skin lesions and blistering in rare disease
This article was originally published in Start Up
Executive Summary
Scioderm Inc. thinks it can break the long string of failures in wound healing with an experimental therapy called Zorblisa, which it is developing as a topical treatment for epidermolysis bullosa, a rare connective tissue disease that causes skin to tear easily. The FDA has designated it a breakthrough therapy; if Phase III data look good, Scioderm could bring Zorblisa to market in the US and Europe by the end of 2016.